Delving into the Latest Updates on Sound Biopharmaceuticals Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Hemic and Lymphatic Diseases

Bispecific antibody

Monoclonal antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Hemic and Lymphatic Diseases	1
Immune System Diseases	1

Top 5 Drug Type	Count

Bispecific antibody	2
Monoclonal antibody	2

Top 5 Target	Count

4-1BB(Tumor necrosis factor receptor superfamily member 9)	1
4-1BBL x 5T4	1
CD38(Lymphocyte differentiation antigen CD38)	1

主要目的是评价FTL001在晚期复发转移和难治性实体瘤受试者中的安全性和耐受性。次要目的包括评价 FTL001的初步抗肿瘤活性、药代动力学（PK）特征和免疫原性等。探索目的包括探索FTL001的药效学特征、相关生物标志物与抗肿瘤疗效的关系等。

[Translation]

The primary objective is to evaluate the safety and tolerability of FTL001 in subjects with advanced recurrent metastatic and refractory solid tumors. Secondary objectives include evaluating the preliminary anti-tumor activity, pharmacokinetic (PK) characteristics and immunogenicity of FTL001. Exploratory objectives include exploring the pharmacodynamic characteristics of FTL001, the relationship between relevant biomarkers and anti-tumor efficacy, etc.

Start Date16 May 2023

Sponsor / Collaborator

Sound Biopharmaceuticals Ltd.

[+1]

100 Clinical Results associated with Sound Biopharmaceuticals Ltd.

Login to view more data

0 Patents (Medical) associated with Sound Biopharmaceuticals Ltd.

Login to view more data

100 Deals associated with Sound Biopharmaceuticals Ltd.

Login to view more data

100 Translational Medicine associated with Sound Biopharmaceuticals Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

IND Application

1

3

Phase 1 Clinical

Other

7

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

FTL-008.16 ( 4-1BBL x 5T4 )	Advanced Malignant Solid Neoplasm More	Phase 1
FTL-001 ( 4-1BB )	Advanced Malignant Solid Neoplasm More	Phase 1
FTL004 ( CD38 )	Multiple Myeloma More	Phase 1
FTL008.7	-	IND Application
FTL-008.18	Neoplasms More	Discontinued